Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01065467 · ClinicalTrials.gov registry record · Phase 1
Panobinostat (LBH589) in Patients With Metastatic Melanoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01065467 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 16 participants.
The verdict
NCT01065467, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safety of LBH589 as well as to find out what side effects it may cause and how effective it is against melanoma. LBH589 is a drug which may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes, which are proteins normally produced by cells. These enzymes are known to play an important role in the development and reproduction of cancer cells. It is believed that LBH589 works by helping to promote the activity of enzymes which turn on the mechanisms in our cells that suppress cells from becoming cancerous.
Interventions
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-02 |
| Est. Completion | 2017-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01065467
The ClinicalTrials.gov registry entry for NCT01065467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589 is the first listed.
NCT01065467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01065467 about?
NCT01065467 is a clinical study titled "Panobinostat (LBH589) in Patients With Metastatic Melanoma". The purpose of this research study is to determine the safety of LBH589 as well as to find out what side effects it may cause and how effective it is against melanoma. LBH589 is a drug which may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes, which are proteins...
What is the current status of trial NCT01065467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-02. Estimated completion is 2017-03-13.
What interventions are being tested in trial NCT01065467?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT01065467?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.